Resistance to braf inhibitors: ezh2 and its downstream targets as potential therapeutic options in melanoma

HIGHLIGHTS

• who: Anne Uebel and colleagues from the Department of Dermatology and Venereology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany have published the research work: Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma, in the Journal: (JOURNAL) of 22/04/2021

SUMMARY

Depending on the interaction, EZH2 modulates both the activation and repression of gene_expression. In the previous work, the authors noticed decreasing levels of EZH2 in BRAFV600E -mutated melanoma cells treated with vemurafenib, while cells resistant to BRAF inhibitors showed an . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.